The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: Possible involvement in the PPARγ pathway

Carcinogenesis

Volumn 25, Issue 10, 2004, Pages 1805-1812

  DeCicco, Kathleen L ^a   Tanaka, Takemi ^a   Andreola, Fausto ^a   De Luca, Luigi M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; THALIDOMIDE; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 6444240653     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh210     Document Type: Article

References (30)

1. Jemal,A., Murray,T., Samuels,A., Ghafoor,A., Ward,E. and Thun,M.J. (2003) Cancer Statistics, 2003. CA Cancer J. Clin., 53 5-26.
2. Beadsmoore,C.J. and Screaton,N.J. (2003) Classification, staging and prognosis of lung cancer. Eur. J. Radiol., 45, 8-17.
3. Brock,C.S. and Lee,S.M. (2002) Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. Eur. Respir. J. 19, 557-570.
4. Shepherd,F.A. (2001) Angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer, 34, 81-89.
5. D'Amato,R.J., Loughnan,M.S., Flynn,E. and Folkman,J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA 91, 4082-4085.
6. Raje,N. and Anderson,K.C. (2002) Thalidomide and immunomodulatory drugs as cancer therapy. Curr. Opin. Oncol., 14 635-640.
7. McBride,W.G. (1961) Thalidomide and congenital abnormalities. Lancet, 1358, 2.
8. Meierhofer,C., Dunzendorfer,S. and Wiedermann,C.J. (2001) Theoretical basis for the activity of thalidomide. Biodrugs, 15 681-703.
9. Richardson,P., Hideshima,T. and Anderson,K. (2002) Thalidomide: emerging role in cancer medicine. Annu. Rev. Med., 53, 629-657.
10. Fanelli,M., Sarmiento,R., Gattuso,D., Carillio,G., Capaccetti,B., Vacca,A., Roccaro,A.M. and Gasparini,G. (2003) Thalidomide: a new anticancer drug? Exp. Opin. Invest. Drugs, 12 1211-1225.
11. Berger,J. and Moller,D.E. (2002) The mechanisms of action of PPARs. Annu. Rev. Med., 53, 409-435.
12. Qi,C., Zhu,Y. and Reddy,J.K. (2000) Peroxisome proliferator-activated receptors, coactivators and downstream targets. Cell Biochem. Biophys., 32, 187-204.
13. Chinetti,G., Fruchart,J.-C. and Staels,B. (2000) Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 49, 497-505.
14. Daynes,R.A. and Jones,D.C. (2002) Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol., 2, 748-759.
15. Delerive,P., Fruchart,J.C. and Staels,B. (2001) Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol., 169, 453-459.
16. Sasaki,H., Tanahashi,M., Yukiue,H. et al. (2002) Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer, 36, 71-76.
17. Chang,T.H. and Szabo,E. (2002) Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res., 60, 1129-1138.
18. Tsubouchi,Y., Sano,H., Kawahito,Y., Mukai,S., Yamada,R., Kohno,M., Inoue,K., Hla,T. and Kondo,M. (2000) Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem. Biophys. Res. Commun., 270, 400-405.
19. Ching,L.M., Xu,Z.F., Gummer,B.H., Palmer,B.D., Joseph,W.R. and Baguley,B.C. (1995) Effect of thalidomide on tumour necrosis factor production and anti-tumor activity induced by 5,6-dimethylxantheone-5-acetic acid. Br. J. Cancer, 72, 339-343.
20. Geitz,H., Handt,S. and Zwingenberger,K. (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology, 31, 213-221.
21. Noguchi,T., Shimazawa,R., Nagasawa,K. and Hashimoto,Y. (2002) Thalidomide and its analogues as cyclooxygenase inhibitors. Bioorg. Med. Chem. Lett., 12, 1043-1046.
22. Haslett,P.A., Corral,L.G., Albert,M. and Kaplan,G. (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. J. Exp. Med., 187, 1885-1892.
23. Yu,S., Matsusue,K., Kashireddy,P., Cao,W.-Q., Yeldandi,V., Yeldandi,AV., Rao,MS., Gonzalez,FJ. and Reddy,J.K. (2003) Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor γ1 (PPAR γ1) overexpression. J. Biol. Chem., 278, 498-505.
24. Agarwal,VR., Bischoff,E.D., Hermann,T. and Lamph,W.W. (2000) Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (Targretin). Exp. Ther., 60, 6033-6038.
25. Mukhopadhyay,T., Roth,J.A. and Maxwell,S.A. (1995) Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene, 11, 999-1003.
26. Arenberg,D.A., Kunkel,S.L., Polverini,P.J., Glass,M., Burdick,M.D. and Strieter,R.M. (1996) Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest., 97, 2792-2802.
27. Arenberg,D.A., Keane,M.P., DiGiovine,B., Kunkel,S.L., Morris,S.B., Xue,Y.Y., Burdick,M.D., Glass,M.C., Iannettoni,M.D. and Strieter,R.M. (1998) Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J. Clin. Invest., 102, 465-472.
28. Gridelli,C., Maione,P., Airoma,G. and Rossi,A. (2002) Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Curr. Med. Chem., 9, 1851-1858.
29. Tsujii,M., Kawano,S., Sawaoka,H., Hori,M. and DuBois,R.N. (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93, 705-716.
30. Fujita,J., Mestre,J.R., Zeldis,J.B., Subbaramaiah,K. and Dannenberg,A.J. (2001) Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin. Cancer Res., 7, 3349-3355.